Stridebio Inc., a company developing adeno-associated viral (AAV) vectors for in vivo gene therapies, has raised $15.7 million in an oversubscribed series A financing, money the company said will enable it to move multiple programs toward the clinic, with the first likely to reach proof of concept within the next six to nine months.